Trials / Not Yet Recruiting
Not Yet RecruitingNCT06393673
A Study to Find the Best Dose of HS-10384 to Treat Vasomotor Symptoms in Postmenopausal Women
A Randomized, Double-blind, Placebo-controlled, Phase 2 Study to Investigate the Efficacy and Safety of HS-10384 in Postmenopausal Women Suffering From Vasomotor Symptoms (Hot Flashes)
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 195 (estimated)
- Sponsor
- Hansoh BioMedical R&D Company · Industry
- Sex
- Female
- Age
- 40 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
A randomized, double-blind, placebo-controlled phase 2 clinical study to evaluate the efficacy and safety of HS-10384 in postmenopausal women suffering from vasomotor symptoms.
Detailed description
The phase 2 study is consisted with 2 doses. The aim is to detect the efficacy, safety, pharmacokinetics and pharmacodynamics characteristics of HS-10384 in participants with vasomotor symptoms.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HS-10384 tablet Dose 1 | Administered orally QD |
| DRUG | HS-10384 tablet Dose 2 | Administered orally QD |
| DRUG | HS-10384-matched placebo tablets | Administered orally QD |
Timeline
- Start date
- 2024-05-30
- Primary completion
- 2025-06-30
- Completion
- 2025-09-30
- First posted
- 2024-05-01
- Last updated
- 2024-05-01
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06393673. Inclusion in this directory is not an endorsement.